Anti-Diabetes Drugs - D-A-CH

D-A-CH

The projected revenue for the Anti-Diabetes Drugs market in the D-A-CH region is estimated to reach US$3.12bn by 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 7.17%, leading to a market volume of US$4.41bn by 2029.
In comparison to other countries worldwide, United States is anticipated to generate the highest revenue, amounting to US$37,840.00m in 2024.
In the D-A-CH region, Germany leads the way in the market for anti-diabetes drugs with a strong focus on innovative treatment options.

Key regions: India, Australia, Italy, Europe, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Diabetes Drugs market in D-A-CH has been experiencing significant growth in recent years.

Customer preferences: The increasing prevalence of diabetes in the D-A-CH region has led to a rise in demand for anti-diabetes drugs. Patients are increasingly looking for drugs that are effective in managing their condition, while also being affordable and easy to use. As a result, there has been a growing demand for oral anti-diabetes drugs that offer convenient dosing and fewer side effects.

Trends in the market: One of the key trends in the Anti-Diabetes Drugs market in D-A-CH has been the growing popularity of SGLT2 inhibitors. These drugs work by preventing the reabsorption of glucose in the kidneys, thereby reducing blood sugar levels. SGLT2 inhibitors have been shown to be effective in managing diabetes, and they have also been associated with a lower risk of cardiovascular events.Another trend in the market has been the increasing use of combination therapies. Many patients with diabetes require multiple medications to manage their condition, and combination therapies offer a convenient way to take these drugs together. Combination therapies can also be more effective than single-drug therapies, as they target multiple pathways involved in diabetes.

Local special circumstances: In Germany, the Anti-Diabetes Drugs market has been impacted by the country's statutory health insurance system. The system places a strong emphasis on cost-effectiveness, which has led to a focus on generic drugs and biosimilars. This has put pressure on manufacturers to offer competitive pricing for their products.In Switzerland, the Anti-Diabetes Drugs market has been influenced by the country's high per capita income. This has led to a greater willingness among patients to pay for newer, more expensive drugs that offer better outcomes. However, the country's strict regulatory environment has made it difficult for some drugs to gain approval.

Underlying macroeconomic factors: The Anti-Diabetes Drugs market in D-A-CH has been driven by a combination of factors, including an aging population, rising rates of obesity, and increasing awareness of diabetes. These trends are expected to continue in the coming years, which will likely lead to further growth in the market.In addition, the D-A-CH region has a strong healthcare infrastructure, which has helped to support the growth of the Anti-Diabetes Drugs market. The region's high levels of research and development, as well as its well-educated workforce, have made it an attractive location for pharmaceutical companies looking to develop new drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.